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Abstract
Background: The value and utility of self-monitoring of blood glucose (SMBG) in non-insulin treated T2DM has yet to 
be clearly determined. Findings from studies in this population have been inconsistent, due mainly to design 
differences and limitations, including the prescribed frequency and timing of SMBG, role of the patient and physician in 
responding to SMBG results, inclusion criteria that may contribute to untoward floor effects, subject compliance, and 
cross-arm contamination. We have designed an SMBG intervention study that attempts to address these issues.
Methods/design: The Structured Testing Program (STeP) study is a 12-month, cluster-randomised, multi-centre clinical 
trial to evaluate whether poorly controlled (HbA1c ≥ 7.5%), non-insulin treated T2DM patients will benefit from a 
comprehensive, integrated physician/patient intervention using structured SMBG in US primary care practices. Thirty-
four practices will be recruited and randomly assigned to an active control group (ACG) that receives enhanced usual 
care or to an enhanced usual care group plus structured SMBG (STG). A total of 504 patients will be enrolled; eligible 
patients at each site will be randomly selected using a defined protocol. Anticipated attrition of 20% will yield a sample 
size of at least 204 per arm, which will provide a 90% power to detect a difference of at least 0.5% in change from 
baseline in HbA1c values, assuming a common standard deviation of 1.5%. Differences in timing and degree of 
treatment intensification, cost effectiveness, and changes in patient self-management behaviours, mood, and quality 
of life (QOL) over time will also be assessed. Analysis of change in HbA1c and other dependent variables over time will 
be performed using both intent-to-treat and per protocol analyses. Trial results will be available in 2010.
Discussion: The intervention and trial design builds upon previous research by emphasizing appropriate and 
collaborative use of SMBG by both patients and physicians. Utilization of per protocol and intent-to-treat analyses 
facilitates a comprehensive assessment of the intervention. Use of practice site cluster-randomisation reduces the 
potential for intervention contamination, and inclusion criteria (HbA1c ≥ 7.5%) reduces the possibility of floor effects. 
Inclusion of multiple dependent variables allows us to assess the broader impact of the intervention, including 
changes in patient and physician attitudes and behaviours.
Trial Registration: Current Controlled Trials NCT00674986.
Background
Over the past few decades, self-monitoring of blood glu-
cose (SMBG) has been recognized as a core component
of effective diabetes self-management [1-4]. This has
been supported by a plethora of research that has consis-
tently demonstrated that SMBG is a key contributor to
good glycaemic control among insulin-using patients
with type 1 (T1DM) [5,6] and type 2 diabetes (T2DM) [7-
9]. It remains uncertain, however, whether SMBG is effi-
cacious among the large number of T2DM patients who
do not use insulin. Results to date have been decidedly
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mixed, with some studies pointing to significant glycae-
mic benefits resulting from SMBG use [10-14], while oth-
ers have shown no significant benefits [15-18]. Given the
costly nature of current T2DM care, especially as the
worldwide prevalence of T2DM continues to grow rap-
idly, it is critical to determine whether resources devoted
to SMBG are justified and being applied effectively.
Therefore, using randomised controlled trial (RCT)
methodology, this study seeks to test the effects of SMBG
on metabolic outcomes in insulin naÏve T2DM patients,
with special attention devoted to identifying those condi-
tions under which SMBG is or is not beneficial.
This RCT is based on a comprehensive, critical review
of the six largest RCTs that included insulin-naÏve T2DM
patients [12-14,16-18] and published summaries of the
literature [19-22]. Our review suggests that the inconsis-
tent findings found in the literature to date may have
resulted from problems in the actual SMBG intervention.
These problems point to underlying concerns about the
design of fut ure st udies, all of which ha ve been raised
recently by expert working groups [23,24]. If the actual
benefit of SMBG in this population is to be determined
definitively, careful attention must be given to these
potential limitations; most importantly, we must be cer-
tain that the actual SMBG intervention itself is adequate,
and that the study design permits a reasonable examina-
tion of the research question. Because our study builds
upon the previous literature, we raise several questions
about major research design and study implementation
issues and then show how these issues are addressed in
the new study.
How adequate was the SMBG intervention?
SMBG is only one component of a larger diabetes man-
agement regimen. The potential value of SMBG lies in
the subsequent actions which may result from its use,
including actions that the patient makes directly (e.g.,
adjusting his/her dietary intake) and/or indirectly (e.g.,
sharing results with his/her healthcare provider (HCP),
who may then recommend treatment changes). Without
consideration of this context, efforts to assess any value
associated with the simple act of blood glucose monitor-
ing (e.g., the number of blood glucose tests/day) is rela-
tively meaningless. Therefore, we view effective SMBG as
a "package" of behaviours, a multi-component interven-
tion that surrounds SMBG actions. In particular, an effec-
tive intervention must include three key elements: 1)
recommended SMBG frequency and timing (is the pre-
scribed testing regimen sufficiently frequent and compre-
hensive that meaningful and actionable glucose data can
be obtained?); 2) patient response to SMBG results (do
patients make use of their SMBG data appropriately?);
a n d  3 )  H C P  u s e  o f  S M B G  r e s u l t s  ( d o  H C P s  v i e w  t h e
SMBG results and make treatment adjustments as
needed?). Many SMBG interventions reported in the lit-
erature were not comprehensive and were missing key
components, thus limiting their potential impact on
defined outcomes.
What is optimal SMBG frequency and timing?
How many blood glucose tests are enough? Should test-
ing take place at specified times during the day to account
for postprandial spikes or the impact of other activities?
Across the six RCTs, recommended SMBG frequency
was 6 - 8 tests/week, with some but not all recommend-
ing postprandial testing. Assuming that the purpose is to
collect enough data so that patients and/or their HCPs
can see recognizable patterns and be confident about tak-
ing corrective action, is this frequency and timing suffi-
c i e n t ?  M o s t  s t u d i e s ,  h o w e v e r ,  d o  n o t  p r o v i d e  a  c l e a r
rationale to justify the frequency and timing of testing
included in their protocols. Although there are no data
that have established a clear threshold for optimal SMBG
frequency, there is preliminary evidence suggesting that
relatively intensive and structured SMBG, which includes
preprandial and postprandial testing over three consecu-
tive days, may be useful [2,23]. Furthermore, this form of
intensive monitoring may make it easier for patients to
see the glycaemic impact of their own actions, which can
enhance their interest and willingness to engage in posi-
tive lifestyle changes.
Do patients make use of SMBG results?
It is often assumed that SMBG functions like other feed-
back devices (e.g., pedometers) to promote corrective
action. If patients do not use SMBG data appropriately,
however, then the mere act of blood glucose monitoring
may be pointless. Only three of the RCTs we reviewed
[12-14] indicated that patients did interpret and respond
to their SMBG results. For example, Guerci and col-
leagues [12] found that the percentage of patients follow-
ing dietary recommendations remained constant over
time in the SMBG arm and decreased significantly in the
control arm, suggesting that maintaining dietary adher-
ence was facilitated by the use of SMBG results. Thus, an
effective SMBG intervention must include ways to assist
patients in making effective use of SMBG data.
Do HCPs make use of SMBG data?
A key value of SMBG is that it can provide HCPs with the
information they need to make timely adjustments in
medication and to make focused lifestyle recommenda-
tions. When this occurs, it can also help patients to see
that their personal efforts to collect SMBG data are
worthwhile, thus contributing to patients' ongoing moti-
vation to continue SMBG over time. Nevertheless, two of
the six RCTs [17,18] did not provide HCPs with access to
SMBG data. Not surprisingly, these RCTs found that
SMBG use was not associated with a significant improve-Polonsky et al. BMC Family Practice 2010, 11:37
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ment in glycaemic control. In contrast, several other
studies provided HCPs with SMBG data to monitor and
adjust therapy and as a basis for discussion with patients
about their regimen [13,14]. A significant beneficial
impact of SMBG was observed in these studies. In sum,
these findings suggest that an effective SMBG interven-
tion should include HCPs working closely and collabora-
tively with their patients, with SMBG data made available
to both.
What is the HbA1c level of patients accepted for study?
Statistically, it would be very difficult to demonstrate
improvements in HbA1c due to any intervention if
patients are already at or near their target HbA1c levels
before the intervention began; there simply would be
insufficient room for improvement to occur (floor effect).
For example, in the DiGEM [16] trial, significant glycae-
mic improvement did not occur in any of the three study
arms over the one-year period. However, mean HbA1c
was 7.5% at baseline, which was at the upper limit of
HbA1c targets for T2DM in the United Kingdom. Under
such circumstances, neither patients nor HCPs may have
been motivated to intensify therapy and, therefore, any
favorable impact due to SMBG would have been difficult
to demonstrate. It is noteworthy that mean baseline
HbA1c was >8.0% in those RCTs that demonstrated a sig-
nificant HbA1c improvement as a result of SMBG [12-
14,17,18]. Therefore, sufficiently high HbA1c levels at
baseline are required in RCTs to prevent floor effects
from occurring.
How can intervention contamination across study arms be 
avoided?
Randomisation of patients within a clinic or practice site
was the most commonly used approach among the six
RCTs. However, within-practice patient randomisation
requires HCPs to become knowledgeable and experi-
enced regarding both the experimental and control pro-
tocols, setting the stage for potential contamination,
which may reduce differences between the arms of the
trial. HCPs may unintentionally make use of the knowl-
edge they acquire working with the intervention group
patients to adjust their treatment of control group
patients. To avoid this kind of contamination, many stud-
ies in primary care employ a cluster-randomisation strat-
egy that randomises practices (not patients) to trial arms
[23,24]. This strategy requires that a diverse set of prac-
t i c e s  i s  r e c r u i t e d  a n d  r a n d o m i s e d  t o  e a c h  a r m .  A l l
patients within a given practice are then assigned to a sin-
gle arm, thus preventing cross-arm contamination.
Do patients complete the entire protocol as required?
If a substantial percentage of patients or HCPs do not
complete the SMBG intervention protocol as required, it
will be difficult to evaluate the effects of the intervention
fairly. In three of the six RCTs (DiGEM, [16] Drew-King
[17], and ESMON [18]) only 48%, 38.5%, and 65%, respec-
tively, of patients completed the prescribed testing
requirements. Most studies employed an intent-to-treat
analysis to evaluate study findings, which does not
account for how well patients actually complied with the
study protocol, thus potentially leading to a faulty inter-
pretation of the results. In situations like these, subse-
quent per protocol analyses may be useful to clarify the
impact, if any, of the actual intervention and to explore
the reasons why some patients regularly complied with
the protocol and others did not. With this knowledge, it is
possible to evaluate the effects of the completed interven-
tion and to identify specific patient or disease-related
characteristics that are associated with poor SMBG
adherence. These can later be used to identify patient
subgroups in need of special attention.
Summary
Due to differences in SMBG intervention protocols and
study designs, the value and utility of SMBG in insulin-
n a Ï v e  T 2 D M  h a s  y e t  t o  b e  d e t e r m i n e d  c l e a r l y .  M a j o r
problems include: comprehensiveness of the prescribed
SMBG intervention itself; lack of a rationale for recom-
mended frequency and timing of SMBG; lack of utiliza-
tion of SMBG findings by patient and HCPs; risk of
intervention contamination that can limit between-group
differences; floor effects that occur when patients have
low levels of HbA1c at baseline; and the low levels of
intervention adherence that can affect outcomes. Conse-
quently, we have designed a study that attempts to
address each of these problems directly, using a protocol
that involves both patients and HCPs in a collaborative
and comprehensive SMBG "package."
Methods/Design
The Structured Testing Program (STeP) Study is a 12-
month, cluster-randomised, multi-centre clinical trial to
evaluate whether poorly controlled, non-insulin treated
T2DM patients benefit from a comprehensive, integrated
physician/patient intervention that uses structured
SMBG. The study protocol was approved by the Coperni-
cus Group (Central IRB) and is in compliance with the
Helsinki Declaration [25].
The primary objective of the study is to determine if an
integrated, intensive, and episodic SMBG intervention is
associated with a significant reduction in HbA1c over 12
months, compared with enhanced usual care. The study
will also examine group differences in: 1) timing and
degree of treatment intensification; 2) changes in patient
self-management behaviours over time; 3) changes in
patient mood and quality of life (QOL) over time; and 4)
cost effectiveness of the intervention.Polonsky et al. BMC Family Practice 2010, 11:37
http://www.biomedcentral.com/1471-2296/11/37
Page 4 of 10
Hypothesis
The overarching hypothesis is that SMBG will lead to sig-
nificant improvement in glycaemic control among non-
insulin treated T2DM patients when it occurs frequently
enough for the detection of actionable glucose patterns,
and when patients and their physicians possess the
knowledge, skills, and willingness to interpret and make
use of SMBG results in a collaborative fashion. More spe-
cifically, we hypothesize that episodic, intensive SMBG -
when used appropriately for enhancing patient under-
standing, promoting patient motivation, and initiating/
adjusting therapy - will significantly improve long-term
blood glucose control in people with poorly controlled
(HbA1c ≥ 7.5%), non-insulin treated T2DM. The practi-
cal, yet comprehensive, SMBG protocol includes: 1) short
periods of intensive SMBG, in which data are recorded
on an easy-to-view, paper-and-pencil form, performed at
least quarterly; 2) patient and physician training in the
effective use of SMBG data; 3) patient presentation of
their SMBG data to their physicians for regular review
and discussion; and 4) physician review and discussion of
SMBG data with their patients, followed by recommen-
dations for therapy change (pharmacologic and non phar-
macologic) as needed. The protocol places significant
emphasis on the collaborative efforts and relationship
between patients and their physicians because both play
critical roles in the appropriate utilization of SMBG data.
Subjects
Thirty-four primary care practice sites in the eastern
United States will be identified and recruited for partici-
pation in the study. The sites will include both small and
large primary care practices, which serve communities
with a range of patient education, social class, and ethnic-
ity that reflects the diversity of primary care settings in
the US. Each site will then be randomly assigned (cluster-
randomised design) via a defined protocol to enhanced
usual care (active control group [ACG]) or enhanced
usual care with structured testing (structured testing
group [STG]). Additional sites may be recruited as
needed to ensure enough patients (minimum of 504
enrolled patients) to adequately power the study.
Two hundred thirty-one patients will be enrolled in the
ACG, and 273 in the STG, which we estimate will lead to
a total of 204 patients completing each arm at 12 months.
Differential enrollment of practices and patients will be
undertaken initially to account for potential differences in
rates of attrition between the two study arms. Each prac-
tice will generate a list of all potential study patients who
meet age, diagnosis, and HbA1c inclusion criteria from
their individual databases or chart review. Participating
physicians will review the list and eliminate any subject
for medical reasons, as required by many human research
committees in the US. Remaining patients will then be
randomly selected from the list, using an external, study-
defined protocol.
Inclusion criteria are: T2DM for greater than one year
that is managed by their primary care physician; age 25 or
more years; HbA1c ≥ 7.5-12.0%; treated by diet, exercise,
oral diabetes medication, and/or injectable incretin
mimetic; read and write English without assistance; and
has not participated in any other research protocol within
the last 30 days. Exclusion criteria are: T1DM; managed
with insulin at the start of study; C-peptide level greater
than 0.50 ng/mL; under the care of an endocrinologist or
diabetologist; used systemic oral or inhaled steroids more
than 14 days within last 3 months; treated with chemo-
therapy or radiation therapy; plans to relocate or travel
extensively during next year; pregnant or breast feeding;
and severe depression or other severe psychological con-
ditions.
Design
The study design is shown in Figure 1. The STG arm will
receive enhanced usual patient care plus a structured
SMBG protocol at least quarterly. Patients in the ACG
arm will visit their physicians quarterly and will continue
their SMBG practice following their physician's recom-
mendations. It is important to note that "usual care" in
both groups involved more frequent clinic visits, point-
of-care HbA1c tests, and free blood glucose meters and
test strips; these additional services and resources are not
generally available in most US primary care practices.
Patients from both arms will be evaluated with the same
scales and measures at the same time intervals over 12
months.
Procedure
STG participants will utilize the Accu-Chek® 360° View
blood glucose analysis system (Tool) (Roche Diagnostics,
Indianapolis, Indiana, USA). The system requires that
patients record three consecutive day SMBG profiles.
Figure 1 Study design.
Primary Care Practices
Appropriate Patients:
T2DM ≥ 1 year managed by PCP
Age ≥ 25 years
HbA1c 7.5% to 12%
Treatment: Lifestyle/OADs                                 
(including incretins) 
Active Control Group
(ACG)
Enhanced Usual Care
Structured Testing Group
(STG)
Enhanced Usual Care with 
Structured SMBGPolonsky et al. BMC Family Practice 2010, 11:37
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Each profile includes seven blood glucose tests/day (pre-
prandial/postprandial at each meal and at bedtime),
along with patient ratings of meal sizes and energy levels
(see Figure 2). Space is provided to plot blood glucose
results for better visualization of trends and patterns.
Guidelines on the form indicate preprandial and post-
prandial blood glucose target ranges. The Tool also pro-
vides space for patients to note any comments or
"learnings" relevant to their SMBG experiences. The Tool
was designed to encourage collaborative discussion
between patients and their physicians. Previous evalua-
tions conducted with both patients and physicians have
demonstrated that patients are willing and able to accu-
rately complete the Tool [26] and that physicians are able
to identify specific glucose patterns, determine the neces-
sity for therapy change, and select specific pharmacologi-
cal and lifestyle changes [26].
Physicians and staff in the ACG and STG arms will be
informed about the clinical investigational plan, including
the rationale for the study, design of the study protocol,
subject-related procedures, and use of evaluation ques-
tionnaires. Patients in both arms will receive a blood glu-
cose meter (Accu-Chek®  Aviva blood glucose meter
system, Roche Diagnostics, Indianapolis, Indiana, USA)
and will be thoroughly trained in its operation. ACG
patients will be instructed to use their meters following
their physician's recommendations.
STG physicians and staff will receive training on inter-
preting the SMBG data provided by the Tool and will be
provided with an algorithm that describes various phar-
macologic/lifestyle treatment strategies that can be uti-
lized in response to the specific SMBG patterns identified
in their analysis of the Tool. STG physicians will be con-
tacted regularly over the 12 months of the study to
enhance the consistency of the intervention over time. All
physicians will be blinded to all study-collected measures
and scales. Point-of-care HbA1c equipment will be pro-
vided to all practices to ensure that any differential avail-
ability of this equipment does not affect outcomes.
STG clinic staff will conduct one-on-one training ses-
sions with each STG patient to teach the SMBG protocol.
This includes instruction in the use of the meter and
Figure 2 Accu-Chek® 360° View blood glucose analysis system.Polonsky et al. BMC Family Practice 2010, 11:37
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administration of a DVD instructional program to
explain and demonstrate how to complete the Tool, inter-
pret the SMBG data, and make appropriate changes in
lifestyle treatments. One-on-one discussions between
patients and staff will provide an opportunity to review
the content and purpose of the SMBG intervention, dis-
cuss what was learned from the DVD, enhance general
understanding, personalize SMBG activities, and address
questions and concerns.
Study duration will be 12 months, with patient visits
occurring at initial screening and baseline, followed by
completion of the Tool prior to visits at months 1, 3, 6, 9,
and 12. The sequence of visits is described below and pre-
sented in Figure 3.
Screening visit
After eligible patients have been identified via study pro-
tocol and contacted by mail, they will be invited to attend
an initial screening visit at their physician's office. At
screening, investigators will describe the study in detail,
obtain written informed consent, record demographics,
collect relevant medical history/lifestyle activities, per-
form physical examinations, collect laboratory samples,
and document all current medications, including vita-
mins and supplements. Patients will also complete the
STeP questionnaire, which assesses disease management
behaviour, mood, quality of life, and diabetes-related self-
efficacy, using validated self-report instruments.
Baseline visit
At the baseline visit, which will occur within 14 days of
screening, clinic staff will provide all patients with a
blood glucose meter and test strips, and patients will be
instructed in the use of their blood glucose monitoring
system. Laboratory results from the screening visit will be
reviewed to ensure inclusion criteria have been met; if
not, subjects will be discontinued from the study . Any
changes in medications, vitamins, and supplements will
be recorded. No diabetes-related treatment changes will
occur during the baseline visit.
Staff will provide STG patients with the Tool and con-
duct one-on-one training with each patient. The instruc-
tional DVD program will be viewed and discussed. STG
patients will be asked to complete the Tool and bring it to
the month 1 visit. ACG patients will not receive the Tool
or any additional SMBG training.
Clinic visits (months 1, 3, 6, 9, and 12)
At subsequent visits, ACG and STG clinic staff will col-
lect laboratory samples and a point-of-care HbA1c test
will be performed. Adverse events and changes in medi-
cations (including vitamins and supplements) will be
recorded and a brief physical examination will be per-
f o r m e d .  P h y s i c i a n s  w i l l  d o c u m e n t  m i s s e d  w o r k  d a y s ,
changes in medical history and lifestyle activities. In addi-
tion, patients in both groups will bring in their meter so
that data can be uploaded electronically. They also will
report any changes they have made to their diabetes regi-
men since they were last seen. ACG and STG patients will
complete the STeP questionnaire (months 3, 6, 9, and 12),
as well as a post-visit questionnaire at each visit to assess
patient satisfaction with the visit and to record patient
reports of any physician recommendations for pharmaco-
logic and/or lifestyle changes that occurred during the
visit. STG patients also will be asked if they brought their
360 View SMBG Tool to the visit and if their physician
reviewed the form with them.
In reviewing the Tool, areas of needed regimen change
will be identified and treatment changes based on this
information will be made jointly. Depending on the treat-
ment changes recommended, STG patients may be asked
to complete an additional Tool within the next few weeks
to evaluate the effectiveness of the new treatment
changes and to determine if additional changes are war-
ranted. In all cases, another Tool will be provided to the
STG patients at the end of each visit, to be completed
during the week preceding each patient's next quarterly
visit. One week prior to their next scheduled office visit,
STG patients will be prompted via telephone by their
physician's office to complete the Tool.
Measures
Primary Endpoint
The primary endpoint is glycaemic control, as assessed by
change in HbA1c from baseline over 12 months. Blood
samples will be collected at screening and the scheduled
clinic visits (months 3, 6, 9, and 12). HbA1c analysis will
be conducted by a central laboratory (Covance, Indianap-
olis, Indiana, USA). All scales and measures will contain
patient codes rather than patient identifiers. Patient iden-
tifiers will be restricted to their physician's and to senior
investigators.
Secondary Endpoints
Treatment Intensification Treatment intensification
includes two components. The first is pharmacologic
modification, which is defined as the initiation of a new
medication, the increase or decrease in the dose of an
existing medication, or the termination of an existing
medication. The second is recommended lifestyle modifi-
cation, which is defined as any change in diet, exercise, or
other management approaches. The total number of vis-
its with recommended medication or lifestyle modifica-
tions and the time to the first treatment change will be
recorded for all subjects.
STeP Questionnaire The STeP questionnaire incorpo-
rates the questions from standard psychometric instru-
ments, as well as commonly used survey questions, to
assess disease management behaviour, diabetes self-effi-
cacy, well-being, depression, and diabetes-specific dis-
tress. Questions were drawn from the: 1) International
Physical Activity Questionnaire (Short Form) [27]; 2)Polonsky et al. BMC Family Practice 2010, 11:37
http://www.biomedcentral.com/1471-2296/11/37
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NCI Fruit & Vegetable Screener [28]: 3) National Cancer
Institute (NCI) Percent Energy From Fat Screener [29]; 4)
Hill-Bone Compliance to Medication Scale [30]; 5) Self-
Monitoring of Blood Glucose (SMBG) [31]; 6) Treatment
Self-Regulation Questionnaire (TSRQ) [32]; 7) Confi-
dence in Diabetes Self-Care (CIDS-Type 2) [33]; 8)
WHO-5 Well-Being Index (1998) [34]; 9) Diabetes Dis-
tress Scale (DDS) [35]; and 10) Patient Health Question-
naire 8 (PHQ-8) [36]. Clinic staff will be blinded from
viewing these data.
Patient Post-Visit Survey This survey records the sub-
ject's visit satisfaction and documents patient-reported
treatment changes that were recommended by the physi-
cian during the visit. For STG patients, information on
the usage of the Tool by both subject and physician will
be collected.
Blood glucose meter data SMBG data from both patient
groups will be uploaded by the site coordinator directly to
a web server at each study visit from the blood glucose
meter via the Accu-Chek® Smart Pix device (Roche Diag-
nostics, Indianapolis, Indiana, USA). Clinic staff will be
blinded from viewing these data.
Clinical Data Clinical laboratory evaluations will include
hematolology, chemistry/immunology urinalysis, and
point-of-care (HbA1c). Weight, height, blood pressure,
pulse, respiration, and temperature will be recorded in
the medical record and transcribed on the electronic
record forms, where appropriate. A complete physical
examination will be performed at screening and a brief
physical examination will be performed at months 1, 3, 6,
9, and 12.
Statistical analysis
I n  a  c l u s t e r - r a n d o m i s e d  s t u d y ,  p a t i e n t s  w i t h i n  a  g i v e n
cluster (in this case a clinical practice) often share many
characteristics (e.g. ethnicity socioeconomic status, edu-
cation level). Estimation of sample size, based on the
assumption of the independence of individual observa-
tions, therefore may be inaccurate. Proper estimation of
sample size for cluster-based studies requires estimates of
Figure 3 Clinic visit schedule.
• Collect/record demographic, 
personal, medical, laboratory data
• Complete STeP Subject 
Questionnaire 
• Provide Tool and conduct one-on-one 
training, using DVD
• Remind patients to bring complete a 
new tool 1 week prior to next visit
Screening
Baseline 
Visit
Month 1
Clinic Visit
Month 3
Clinic Visit
Month 6
Clinic Visit
Month 9
Clinic Visit
Month 12
Clinic Visit
• Dispense testing materials
• SMBG meter training
• Review laboratory data, medication 
changes recorded
• Schedule Month 1 visit
• Collect laboratory samples, perform 
point-of-care HbA1c test
• Upload data from blood glucose 
meter
• Perform physical exam, document 
adverse events and changes in 
medication
• Complete Post-Visit Questionnaire 
(all visits)
• Complete 360° Subject 
Questionnaire (Months 3, 6, 9, 12)
• Schedule next clinic visit
• Review completed Tool with patient, 
make therapy changes as needed
• Dispense new Tool and additional 
SMBG materials as needed
• Remind patients to bring complete a 
new tool 1 week prior to next visit and 
bring it to visit
ACG and STG Patients
STG Patients onlyPolonsky et al. BMC Family Practice 2010, 11:37
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the intra-class correlation coefficient (ICC) for each out-
come variable of interest [37].
With change in HbA1c as the primary outcome vari-
able, and using a two-sample t-test (two-sided, α = 0.05),
a sample size of 204 per arm will have 90% power to
detect a difference of at least 0.5% in change from base-
line in HbA1c values, assuming a common standard devi-
ation (SD) of 1.5%. The estimate of SD in HbA1c values
was inflated from 1.15 to 1.50 due to the clustering effect
[37,38].
Analysis of Dependent Variables
The analysis of change in HbA1c and other dependent
variables (e.g. self-management behaviours) over time
will be performed in two ways. First, the analysis will
focus on the intent-to-treat (ITT) population, defined as
all subjects who completed the baseline visit, regardless
of their subsequent participation or compliance in the
protocol over time. There will be no imputation of miss-
ing data values; however, a mechanism relevant to the
missing data will be taken into account by using Linear
Mixed Models (LMM) with SAS PROC MIXED, where it
is assumed, initially, that the missing measurements of
HbA1c are missing at random. Additional analyses of
patient attrition at each step in the protocol from screen-
ing through the 12 month assessment also will be under-
taken.
The second approach will be a per protocol (PP) analy-
sis, which will compare ACG patients, STG patients who
complied with the protocol, and STG patients who did
not comply with the protocol. Compliance is defined as
those STG patients who, at >4 clinic visits (out of a possi-
ble five visits), completed at least 80% of all blood glucose
values on the Tool, brought their completed Tool to the
clinic visit, and reported that their physicians looked at
the Tool and discussed the results. This analysis will
enable us to determine the effect of the SMBG interven-
tion among those STG patients and physicians who par-
ticipated fully in the program, compared to those who did
not.
Additional Analyses (ITT and PP)
Mediator analyses These analyses will examine whether
critical variables, such as total number of visits, treatment
intensification, physician recommendations for pharma-
cologic and/or lifestyle changes, frequency of Tool use,
and changes in patient self-management behaviours (e.g.,
level of physical activity), mediated the effects of mem-
bership in each study arm on the primary and secondary
outcomes over time.
Moderator analyses These analyses will observe the
effects of baseline patient and physician characteristics
on subsequent outcomes over time. For example, we will
explore the impact of baseline levels of patients'
depressed mood, use of SMBG, number of medications,
diabetes-related distress, and diabetes self-efficacy on
outcomes. The impact of physician practice characteris-
tics (e.g., years in practice, clinic size) will also be exam-
ined as they affect outcomes.
Discussion
Given the growing worldwide diabetes epidemic, it is
critical that resources devoted to diabetes management
are applied effectively. Although the benefits of SMBG in
T1DM and insulin treated T2DM are well-supported in
the literature [5-9], the value and utility of SMBG in non-
insulin-treated T2DM remains uncertain. Much of this
uncertainty stems from notable differences among previ-
ous studies; most importantly, the adequacy of the study
design to accurately measure the impact of SMBG and
the adequacy of the SMBG intervention itself.
In designing the current study, we have attempted to
address these limitations, with an emphasis on appropri-
ate utilization of SMBG data by both patients and physi-
cians working together. Building upon previous trials, our
study addresses the value of SMBG as a method to
enhance patient motivation and understanding of their
disease, to modify patient behaviour in support of health-
ier lifestyles and to guide and support therapeutic
changes by both physicians and patients. Furthermore,
we have selected a large group of primary care practices
to ensure a diverse patent population and have taken
active steps to reduce a variety of potential biases through
the use of randomisation procedures.
I t  i s  i m p o r t a n t  t o  n o t e  t h a t  t h e  i n t e r v e n t i o n  i s  n o t
directed at just patient use of the paper Tool; rather, it
involves both patient and physician behaviours and
knowledge, which are impacted by the parallel tracks of
intervention training. Moreover, the intervention empha-
sizes a collaborative relationship between patient and
physician. Thus, we have conceptualized our SMBG
intervention as not just the act of determining a blood
glucose value; but rather, as both patients and physicians
making appropriate use of SMBG data through informed
treatment decisions. The results of this trial will be avail-
able in 2010.
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